Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00162123 · ClinicalTrials.gov registry record · Phase 2
A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies
A Phase 2 study of Melanoma, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 248
- Enrollment target
- 20
- Study locations
NCT00162123 is a Phase 2 study of Melanoma that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 248 participants, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (65% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT00162123, a Phase 2 study of Melanoma, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 248 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study was to evaluate the continued use of ipilimumab in patients who had reinduction at the time of disease progression or to continue maintenance treatment. In addition, this study will continue to follow patients who have taken ipilimumab, but who are not eligible for maintenance or reinduction therapy.
Conditions Studied
Interventions
- DRUG Ipilimumab
Study Locations (20)
California
- Wilshire Oncology Medical Group Inc - Laverne
- The Angeles Clinic & Research Inst. - Los Angeles
- Usc/Norris Comprehensive Cancer Center - Los Angeles
- San Francisco Oncology Associates - San Francisco
Missouri
- St Joseph Oncology Inc - Saint Joseph
- Washington University School Of Medicine - St Louis
Texas
- Center For Oncology Research & Treatment, P.A. - Dallas
- Joe Arrington Cancer Research And Treatment Center - Lubbock
Arizona
- University Of Arizona Cancer Center - Tucson
Connecticut
- Local Institution - To Come
Florida
- Baptist Cancer Institute - Jacksonville
Illinois
- University Of Chicago - Chicago
Indiana
- Indiana Oncology Hematology Consultants - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 248 participants |
| Start Date | 2006-05 |
| Est. Completion | 2014-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00162123
The ClinicalTrials.gov registry entry for NCT00162123 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 248 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 706-participant average among 266 other Melanoma trials with a reported enrollment target (65% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Melanoma appearing as the primary indexed condition, and to 1 intervention - of which Ipilimumab is the first listed.
NCT00162123 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Missouri, Texas.
Frequently Asked Questions
What is clinical trial NCT00162123 about?
NCT00162123 is a clinical study titled "A Companion Study for Patients Enrolled in Prior/Parent Ipilimumab Studies". The purpose of this study was to evaluate the continued use of ipilimumab in patients who had reinduction at the time of disease progression or to continue maintenance treatment. In addition, this study will continue to follow patients who have taken ipilimumab, but who are not eligible for maintena...
What is the current status of trial NCT00162123?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 248 participants. The study started on 2006-05. Estimated completion is 2014-04.
What conditions does trial NCT00162123 study?
This clinical trial studies the following conditions: Melanoma.
What interventions are being tested in trial NCT00162123?
The interventions under investigation include: Ipilimumab (DRUG).
Who is sponsoring clinical trial NCT00162123?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00162123 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
RECRUITING · Phase 2
-
Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma
RECRUITING · Phase 2
-
A Study of IBI363 in Subjects with Advanced Solid Malignancies
RECRUITING · Phase 2
-
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
RECRUITING · Phase 2
-
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.